Clinical trials: Glucagon
Physiology, Gastroenterology
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in…
- Conditions
- Physiology, Gastroenterology, Endocrinology
- Trial name
- GIP-GLP-gas (NCT01079624)
- Testing
- Glucose-insulinotropic peptide, Glucagon-like peptide-1
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Craniopharyngiomas, Hypothalamic Obesity
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide…
- Trial name
- CRANIOEXE (NCT02860923)
- Testing
- Exenatide
- Where
- 11 sites in France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Bordeaux
Smoking Cessation
Exenatide Once Weekly for Smoking Cessation
The purpose of this study is to identify a potential new treatment for smoking cessation.
- Trial name
- NCT02975297
- Testing
- Exenatide, NRT, Counseling
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- The University of Texas Health Science Center, Houston
GLP-1 Concentration
The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations
Hormones that are produced by our stomach and intestines play a role in regulating our appetite and health. One of the most important hormones is called GLP-1.
- Trial name
- PROCAL (NCT03819972)
- Testing
- Dose response of Capolac®
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bath
Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy
Hepatic Metabolic Changes in Response to Glucagon Infusion
The objective of the study is to investigate how exogenously administered glucagon affects hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting energy expenditure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy, Diabetes Mellitus
- Trial name
- NCT03526445
- Testing
- Glucagon, Saline
- Where
- Denmark
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes
Effect of GLP-1 on Angiogenesis
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications…
- Trial name
- ANGIOSAFE 1 (NCT02686177)
- Testing
- Liraglutide, Metformin or sulfonylurea
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Diabetes Mellitus, Type 2, Diabetes Melletus
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
- Trial name
- ACHIEVE-RAM (NCT07613307)
- Testing
- Orforglipron
- Where
- 40 sites in India, Saudi Arabia and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Esophageal Neoplasms, Stomach Neoplasms
Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer
Surgery is the cornerstone of treatment for patients with oesophageal or gastric cancer, but while surgical removal of the tumour (oesophagectomy or gastrectomy) may offer the best chance of cure, these are major operations…
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02385630
- Testing
- Standardized 400kcal semi-liquid meal
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- St. James's Hospital, Ireland
Acute ST-segment Elevation Myocardial Infarction
Effects of Glucagon Like Peptide-1 on No-reflow
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT02507128
- Testing
- liraglutide
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Chen Wei Ren, MD
Type 2 Diabetes
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.
- Trial name
- NCT02639130
- Testing
- Exendin [9-39]
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)
Glucagon Resistance in Patients With MASLD and T2DM
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).
- Trial name
- NCT07246421
- Testing
- Glugagon
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Type 1 Diabetes
Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's…
- Trial name
- NCT01930097
- Testing
- 14 hours intervention
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Healthy Population, Glucose Tolerance
Effects of Low/No Calorie Sweeteners on Glucose Tolerance
This study aims to determine the effects of chronic exposure to some low/no calorie sweeteners (LNCS) on glucose tolerance and glucagon like peptide 1 (GLP-1) release in healthy individuals.
- Trial name
- NCT04904133
- Testing
- Low/No Calorie Sweeteners
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Acibadem University
Radiation Enteritis
Plasma GLP-2 Dynamics and Acute Radiation Enteritis After Abdominopelvic Radiotherapy
This prospective observational study will enroll 50 adults who are scheduled to receive radiotherapy to the abdomen or pelvis. The study will not assign any additional treatment or change routine clinical care.
- Trial name
- NCT07759258
- Testing
- Abdominopelvic Radiotherapy
- Volunteers
- 50 people
- Sponsor
- Wang Xinying
Alopecia
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days.
- Trial name
- GLP-1 (NCT07783113)
- Testing
- Dietary Supplement for Hair Loss
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Critically Ill, Hypoglycemia
The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients
The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.
- Trial name
- NCT00798590
- Testing
- Glucagon-Like Peptide-1, Saline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Type 2 Diabetes Mellitus
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
By detecting the fasting and postprandial 120-minute glucose, insulin (Insulin, INS), C-peptide (C-peptide, Cp), glucagon (GCG) levels in newly diagnosed type 2 diabetes patients, or the 0-minute, 30-minute, 120-minute glucose…
- Trial name
- NCT06825182
- Testing
- Outpatient newly diagnosed type 2 diabetes subjects, Inpatient newly diagnosed type 2 diabetes subjects
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 1 Diabetes
Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01905020
- Testing
- Carbohydrate-rich meal, Exercise
- Where
- 3 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Drug Overdose, Overdose of Beta-adrenergic Blocking Drug
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
This trial investigates effects of a glucagon bolus injection on heart rate, blood pressure and cardiac output during beta-blocker-induced cardiodepression.
- Trial name
- GLUCAGON (NCT03533179)
- Testing
- Glucagon, Esmolol, Physiologic saline - glucagon dummy
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg